Skip to main content

BuSpar Disease Interactions

There are 5 disease interactions with BuSpar (buspirone).

Major

Anxiolytics/sedatives/hypnotics (applies to BuSpar) depression

Major Potential Hazard, Moderate plausibility.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb PROD (2002):
  2. "Product Information. Ambien (zolpidem)." sanofi-aventis PROD (2001):
  3. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical PROD (2001):
  4. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc PROD (2001):
  5. "Product Information. Equanil (meprobamate)." Wallace Laboratories PROD (2001):
  6. "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories PROD (2001):
  7. "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical PROD (2001):
  8. "Product Information. Xyrem (sodium oxybate)." Orphan Medical (2002):
  9. "Product Information. Lunesta (eszopiclone)." Sepracor Inc (2004):
  10. "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America (2005):
  11. "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals (2010):
  12. "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group (2013):
  13. "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc (2014):
  14. "Product Information. Belsomra (suvorexant)." Merck & Co., Inc (2014):
View all 14 references
Major

Buspirone (applies to BuSpar) renal/liver disease

Major Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction

Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney. In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects. Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.

References

  1. Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986): 41-51
  2. Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987): 547-50
  3. Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988): 171-7
  4. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb PROD (2002):
View all 4 references
Moderate

Anxiolytics/sedatives/hypnotics (applies to BuSpar) glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

References

  1. "Product Information. Benadryl (diphenhydramine)." Parke-Davis PROD (2002):
  2. "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group (2013):
Moderate

Anxiolytics/sedatives/hypnotics (applies to BuSpar) liver disease

Moderate Potential Hazard, Moderate plausibility.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

References

  1. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb PROD (2002):
  2. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical PROD (2001):
  3. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc PROD (2001):
  4. "Product Information. Equanil (meprobamate)." Wallace Laboratories PROD (2001):
  5. "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories PROD (2001):
  6. "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical PROD (2001):
  7. "Product Information. Xyrem (sodium oxybate)." Orphan Medical (2002):
  8. "Product Information. Lunesta (eszopiclone)." Sepracor Inc (2004):
  9. "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America (2005):
  10. "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals (2010):
  11. "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP (2011):
  12. "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc (2014):
  13. "Product Information. Belsomra (suvorexant)." Merck & Co., Inc (2014):
View all 13 references
Moderate

Buspirone (applies to BuSpar) drug dependence

Moderate Potential Hazard, Low plausibility. Applicable conditions: Drug Abuse/Dependence, Alcoholism

In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence. However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb PROD (2002):

BuSpar drug interactions

There are 487 drug interactions with BuSpar (buspirone).

BuSpar alcohol/food interactions

There is 1 alcohol/food interaction with BuSpar (buspirone).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.